clinpsyc.blogspot.com — Pharma industry wonks talk about the “risk/benefit” of new drugs, and yet it seems that these days it’s the public who take the risks and the CEOs and shareholders who get the most benefit. It's all a risk-benefit calculation: How much financial risk do they take by hiding data versus how much can we benefit from aggressively marketing the product